Spots Global Cancer Trial Database for small cell lung cancer limited stage
Every month we try and update this database with for small cell lung cancer limited stage cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Molecular Analysis and Treatment Options of SCLC | NCT05945745 | Small-cell Lung... Small Cell Lung... Small Cell Lung... Small Cell Lung... Small Cell Lung... | Chemotherapy | 18 Years - | Shanghai Chest Hospital | |
Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLC | NCT03214003 | Small Cell Lung... Radiotherapy | SIB Standard | 18 Years - 70 Years | Peking University Cancer Hospital & Institute | |
Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLC | NCT03214003 | Small Cell Lung... Radiotherapy | SIB Standard | 18 Years - 70 Years | Peking University Cancer Hospital & Institute | |
Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy | NCT04418648 | Small Cell Lung... | Toripalimab | 18 Years - 75 Years | Sun Yat-sen University | |
PCI and Brain MRI Follow-up vs Brain MRI Follow-up Alone in Limited-stage SCLC Patients | NCT05651802 | Small Cell Lung... | Prophylactic cr... Thoracic radiot... Chemotherapy | 18 Years - | Zhejiang Cancer Hospital | |
Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC | NCT04189094 | Small Cell Lung... | Sintilimab Etoposide Cisplatin radiotherapy | 18 Years - | Zhejiang Cancer Hospital | |
Immunotherapy as Second-line in Patient With Small Cell Lung Cancer | NCT03059667 | Small Cell Lung... Small Cell Lung... Small Cell Lung... | Atezolizumab Topotecan Carboplatin Etoposide | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
A Prospective Study Comparing Two Radiotherapy Dose/Fraction and Omitting CTVs of the Primary Tumor in Limited SCLC | NCT04543890 | Small Cell Lung... | Hyperfractionat... Hypofractionate... Etoposide Cisplatin | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
Immunotherapy as Second-line in Patient With Small Cell Lung Cancer | NCT03059667 | Small Cell Lung... Small Cell Lung... Small Cell Lung... | Atezolizumab Topotecan Carboplatin Etoposide | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN) | NCT04602533 | Small Cell Lung... | Durvalumab standard of car... | 18 Years - | Johannes Gutenberg University Mainz | |
Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN) | NCT04602533 | Small Cell Lung... | Durvalumab standard of car... | 18 Years - | Johannes Gutenberg University Mainz | |
Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer | NCT01797159 | Small-cell Lung... SCLC Small Cell Lung... | Hippocampal-spa... | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
A Prospective Study Comparing Two Radiotherapy Dose/Fraction and Omitting CTVs of the Primary Tumor in Limited SCLC | NCT04543890 | Small Cell Lung... | Hyperfractionat... Hypofractionate... Etoposide Cisplatin | 18 Years - 75 Years | Zhejiang Cancer Hospital |